Biogen is discontinuing its Alzheimer’s drug Aduhelm, which was approved in 2021 but became snarled in efficacy concerns and payers’ refusals to cover the medication.
Biogen is discontinuing its Alzheimer’s drug Aduhelm, which was approved in 2021 but became snarled in efficacy concerns and payers’ refusals to cover the medication.
Copyright © 2024 | WordPress Theme by MH Themes